Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Olutasidenib (FT-2102) Induces Durable Complete Remissions in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia. Results from a Planned Interim Analysis of a Phase 2 Pivotal Clinical Trial

Jorge E. Cortes, Pierre Fenaux, Karen Yee, Christian Recher, Andrew H. Wei, Pau Montesinos, David C Taussig, Arnaud Pigneux, Thorsten Braun, Antonio Curti, Carolyn Grove, Brian A. Jonas, Asim Khwaja, Pierre Peterlin, Olga Polyanskaya, Jennifer Sweeney, Julie Brevard, Emma Barrett, Stephane De Botton

Blood (2022) 140 (Supplement 1): 6193–6196.

https://doi.org/10.1182/blood-2022-167330

Published: 2022

Journal Articles

Olutasidenib (FT-2102) in Combination with Azacitidine Induces Durable Complete Remissions in Patients with mIDH1 Acute Myeloid Leukemia

Blood (2021) 138 (Supplement 1): 698.

https://doi.org/10.1182/blood-2021-144905

Published: 2021

Journal Articles

Molecular Characteristics of Response to Olutasidenib (FT-2102) in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia

Blood (2021) 138 (Supplement 1): 2351.

https://doi.org/10.1182/blood-2021-144912

Published: 2021

Journal Articles

Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with Azacitidine

Jorge E. Cortes, MD, Eunice S. Wang, MD, Justin M. Watts, MD, Sangmin Lee, MD, Maria R. Baer, MD, Kim-Hien Dao, DO, PhD, Shira Dinner, MD, Jay Yang, MD, William B. Donnellan, MD, Anthony P Schwarer, MD MBBS (Hons), FRACP, FRCPA, Christian Recher, MD PhD, Patrick Kelly, MD, Jennifer Sweeney, Julie Brevard, Patrick Henrick, Sanjeev Forsyth, Sylvie Guichard, Hesham Mohamed, MD, Andrew H. Wei, PhD FRACP, FRCPA, MBBS

Blood (2019) 134 (Supplement_1): 674.

https://doi.org/10.1182/blood-2019-124360

Published: 2019

Journal Articles

Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study

Blood (2019) 134 (Supplement_1): 231.

https://doi.org/10.1182/blood-2019-123920

Published: 2019

Journal Articles

Phase 1 Dose Escalation and Expansion Study to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the BET Inhibitor FT-1101 As a Single Agent in Patients with Relapsed or Refractory Hematologic Malignancies

Manish R. Patel, MD, Guillermo Garcia-Manero, MD, Ronald Paquette, MD, Shira Dinner, MD, William B. Donnellan, MD, Michael R. Grunwald, MD, Maria D Ribadeneira, PhD, Patricia Schroeder, Julie Brevard, Lindsey Wilson, Jennifer Sweeney, Patrick Kelly, MD, Jeffrey E. Lancet, MD

Blood (2019) 134 (Supplement_1): 3907.

https://doi.org/10.1182/blood-2019-124741

Published: 2019

Journal Articles

FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study

Blood (2018) 132 (Supplement 1): 1452.

https://doi.org/10.1182/blood-2018-99-114126

Published: 2018

Journal Articles

Phase 1 Study of the IDH1m Inhibitor FT-2102 As a Single Agent in Patients with IDH1 m Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Justin Watts, MD, Maria R. Baer, MD, Jay Yang, MD, Shira Dinner, MD, Sangmin Lee, MD, Karen Seiter, MD, Thomas Prebet, MD PhD, Gary J. Schiller, MD, Paul Brent Ferrell, Jr., MD, Kim-Hien Dao, DO, PhD, Hagop M. Kantarjian, MD, Patrick Kelly, MD, Ping Li, PhD, Jennifer Sweeney, Courtney Watson, Hesham Mohamed, MD, Jorge E. Cortes, MD

Blood (2018) 132 (Supplement 1): 1453.

https://doi.org/10.1182/blood-2018-99-114263

Published: 2018

Journal Articles

Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma

Blood (2018) 131 (8): 888–898.

https://doi.org/10.1182/blood-2017-08-802470

Published: 2018

Includes: Supplemental data

Journal Articles

Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies

Ian W. Flinn, Susan O’Brien, Brad Kahl, Manish Patel, Yasuhiro Oki, Francine F. Foss, Pierluigi Porcu, Jeffrey Jones, Jan A. Burger, Nitin Jain, Virginia M. Kelly, Kerstin Allen, Mark Douglas, Jennifer Sweeney, Patrick Kelly, Steven Horwitz

Blood (2018) 131 (8): 877–887.

https://doi.org/10.1182/blood-2017-05-786566

Published: 2018

Includes: Supplemental data

Journal Articles

Duvelisib (IPI-145), a PI3K-δ,γ Inhibitor, Is Clinically Active in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

Susan O'Brien, Manish Patel, Brad S. Kahl, MD, Steven M. Horwitz, MD, Francine M. Foss, MD, Pierluigi Porcu, MD, Jennifer Sweeney, Kerstin Allen, MA, Kerrie Faia, MS, Howard M. Stern, MD PhD, Patrick Kelly, MD, Ian Flinn

Blood (2014) 124 (21): 3334.

https://doi.org/10.1182/blood.V124.21.3334.3334

Published: 2014

Journal Articles

Clinical Activity of Duvelisib (IPI-145), a Phosphoinositide-3-Kinase-δ,γ Inhibitor, in Patients Previously Treated with Ibrutinib

Pierluigi Porcu, MD, Ian Flinn, Brad S. Kahl, MD, Steven M. Horwitz, MD, Yasuhiro Oki, John C. Byrd, MD, Jennifer Sweeney, Kerstin Allen, MA, Kerrie Faia, MS, Min Ni, PhD, Howard M. Stern, MD PhD, Patrick Kelly, MD, Susan O'Brien

Blood (2014) 124 (21): 3335.

https://doi.org/10.1182/blood.V124.21.3335.3335

Published: 2014

Journal Articles

a Phase 1 Evaluation of Duvelisib (IPI-145), a PI3K-δ,γ Inhibitor, in Patients with Relapsed/Refractory iNHL

Ian Flinn, Yasuhiro Oki, MD, Manish Patel, Steven M. Horwitz, MD, Francine M. Foss, MD, Jennifer Sweeney, Kerstin Allen, MA, Mark Douglas, MS, Lori Steelman, Joi Dunbar, PharmD, Howard M. Stern, MD PhD, Patrick Kelly, MD, Brad Kahl, MD

Blood (2014) 124 (21): 802.

https://doi.org/10.1182/blood.V124.21.802.802

Published: 2014

Journal Articles

Duvelisib (IPI-145), a Phosphoinositide-3-Kinase-δ,γ Inhibitor, Shows Activity in Patients with Relapsed/Refractory T-Cell Lymphoma

Steven M. Horwitz, MD, Pierluigi Porcu, MD, Ian Flinn, Brad S. Kahl, MD, Jennifer Sweeney, Howard M. Stern, MD PhD, Mark Douglas, MS, Kerstin Allen, MA, Patrick Kelly, MD, Francine M. Foss, MD

Blood (2014) 124 (21): 803.

https://doi.org/10.1182/blood.V124.21.803.803

Published: 2014

Journal Articles

Preliminary Safety and Efficacy Of IPI-145, a Potent Inhibitor Of Phosphoinositide-3-Kinase-δ,γ, In Patients With Chronic Lymphocytic Leukemia

Ian Flinn, MD, PhD, Manish Patel, MD, Brad S. Kahl, MD, Steven M. Horwitz, MD, Francine M. Foss, MD, Yasuhiro Oki, MD, Pierluigi Porcu, MD, Jennifer Sweeney, BS, Kerstin Allen, MA, Kerrie Faia, MS, Patricia Harris, MPH, Joi Dunbar, PharmD, Howard M. Stern, M.D., Ph.D., Patrick Kelly, MD, Susan O'Brien, MD

Blood (2013) 122 (21): 677.

https://doi.org/10.1182/blood.V122.21.677.677

Published: 2013

Journal Articles

Clinical Safety and Activity in a Phase 1 Trial of IPI-145, a Potent Inhibitor of Phosphoinositide-3-Kinase-δ,γ, in Patients with Advanced Hematologic Malignancies

Ian W. Flinn, MD, PhD, Steven M. Horwitz, MD, Manish Patel, MD, Anas Younes, MD, James R. Porter, PhD, Jennifer Sweeney, Kerstin Allen, MA, Patrick Kelly, MD, Brad S. Kahl, M.D.

Blood (2012) 120 (21): 3663.

https://doi.org/10.1182/blood.V120.21.3663.3663

Published: 2012

NARROW

Olutasidenib (FT-2102) Induces Durable Complete Remissions in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia. Results from a Planned Interim Analysis of a Phase 2 Pivotal Clinical Trial

Olutasidenib (FT-2102) in Combination with Azacitidine Induces Durable Complete Remissions in Patients with mIDH1 Acute Myeloid Leukemia

Molecular Characteristics of Response to Olutasidenib (FT-2102) in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia

Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with Azacitidine

Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study

Phase 1 Dose Escalation and Expansion Study to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the BET Inhibitor FT-1101 As a Single Agent in Patients with Relapsed or Refractory Hematologic Malignancies

FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study

Phase 1 Study of the IDH1m Inhibitor FT-2102 As a Single Agent in Patients with IDH1 m Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma

Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies

Duvelisib (IPI-145), a PI3K-δ,γ Inhibitor, Is Clinically Active in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

Clinical Activity of Duvelisib (IPI-145), a Phosphoinositide-3-Kinase-δ,γ Inhibitor, in Patients Previously Treated with Ibrutinib

a Phase 1 Evaluation of Duvelisib (IPI-145), a PI3K-δ,γ Inhibitor, in Patients with Relapsed/Refractory iNHL

Duvelisib (IPI-145), a Phosphoinositide-3-Kinase-δ,γ Inhibitor, Shows Activity in Patients with Relapsed/Refractory T-Cell Lymphoma

Preliminary Safety and Efficacy Of IPI-145, a Potent Inhibitor Of Phosphoinositide-3-Kinase-δ,γ, In Patients With Chronic Lymphocytic Leukemia

Clinical Safety and Activity in a Phase 1 Trial of IPI-145, a Potent Inhibitor of Phosphoinositide-3-Kinase-δ,γ, in Patients with Advanced Hematologic Malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only